Vasantha Jotwani1,2, Rebecca Scherzer1,2, Michelle M Estrella3, Lisa P Jacobson4, Mallory D Witt5, Frank Palella6, Ken Ho7, Michael Bennett8, Chirag R Parikh9,10, Joachim H Ix11,12, Michael Shlipak1,2. 1. Department of Medicine, San Francisco VA Medical Center, San Francisco, CA, USA. 2. Kidney Health Research Collaborative, San Francisco VA Medical Center and University of California, San Francisco, CA, USA. 3. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5. Division of HIV Medicine, Department of Medicine, Harbor-UCLA Medical Center and the Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA. 6. Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, IL, USA. 7. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 8. Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 9. Section of Nephrology, Department of Medicine, Yale University, New Haven, CT, USA. 10. Program of Applied Translational Research, Yale University, New Haven, CT, USA. 11. Division of Nephrology-Hypertension, Department of Medicine, University of California, San Diego, CA, USA. 12. Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.
Abstract
BACKGROUND: Chronic kidney disease (CKD) is common among HIV-infected individuals but serum creatinine is insensitive for detecting kidney damage at early stages. We hypothesized that HIV infection would be associated with elevations in subclinical markers of kidney injury and fibrosis in a contemporary cohort of men. METHODS: In this cross-sectional study, we measured urine levels of interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), pro-collagen type III N-terminal pro-peptide (PIIINP) and albumin-creatinine ratio (ACR) in 813 HIV-infected and 331 uninfected men enrolled in the Multicenter AIDS Cohort Study. RESULTS: Median eGFR was 95 ml/min/1.73 m2 among African-Americans (n=376) and 87 ml/min/1.73 m2 among Caucasians (n=768). Among HIV-infected men, the median CD4 lymphocyte count was 572 cells/mm3 and 76% of men had undetectable HIV RNA levels. After multivariable adjustment for traditional CKD risk factors including eGFR, HIV infection was associated with 52% higher urine IL-18 (95% CI, 33%, 73%), 44% higher KIM-1 (27%, 64%), 30% higher PIIINP (15%, 47%) and 84% higher ACR (54%, 120%), with similar effect sizes among African-Americans and Caucasians (P>0.2 for tests of interaction by race). These associations remained statistically significant in analyses that excluded persons with detectable HIV RNA levels and in models that adjusted for cumulative exposure to tenofovir disoproxil fumarate. CONCLUSIONS: Compared with uninfected men, HIV-infected men had more extensive glomerular and tubulointerstitial damage, as assessed by urine biomarkers. Future studies should evaluate whether combinations of biomarkers can be used to monitor stages of kidney injury and to predict CKD risk in HIV-infected individuals.
BACKGROUND:Chronic kidney disease (CKD) is common among HIV-infected individuals but serum creatinine is insensitive for detecting kidney damage at early stages. We hypothesized that HIV infection would be associated with elevations in subclinical markers of kidney injury and fibrosis in a contemporary cohort of men. METHODS: In this cross-sectional study, we measured urine levels of interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), pro-collagen type III N-terminal pro-peptide (PIIINP) and albumin-creatinine ratio (ACR) in 813 HIV-infected and 331 uninfected men enrolled in the Multicenter AIDS Cohort Study. RESULTS: Median eGFR was 95 ml/min/1.73 m2 among African-Americans (n=376) and 87 ml/min/1.73 m2 among Caucasians (n=768). Among HIV-infectedmen, the median CD4 lymphocyte count was 572 cells/mm3 and 76% of men had undetectable HIV RNA levels. After multivariable adjustment for traditional CKD risk factors including eGFR, HIV infection was associated with 52% higher urine IL-18 (95% CI, 33%, 73%), 44% higher KIM-1 (27%, 64%), 30% higher PIIINP (15%, 47%) and 84% higher ACR (54%, 120%), with similar effect sizes among African-Americans and Caucasians (P>0.2 for tests of interaction by race). These associations remained statistically significant in analyses that excluded persons with detectable HIV RNA levels and in models that adjusted for cumulative exposure to tenofovir disoproxil fumarate. CONCLUSIONS: Compared with uninfected men, HIV-infectedmen had more extensive glomerular and tubulointerstitial damage, as assessed by urine biomarkers. Future studies should evaluate whether combinations of biomarkers can be used to monitor stages of kidney injury and to predict CKD risk in HIV-infected individuals.
Authors: J A Winston; L A Bruggeman; M D Ross; J Jacobson; L Ross; V D D'Agati; P E Klotman; M E Klotman Journal: N Engl J Med Date: 2001-06-28 Impact factor: 91.245
Authors: Leslie A Bruggeman; Michael D Ross; Nozomu Tanji; Andrea Cara; Steven Dikman; Ronald E Gordon; Godfrey C Burns; Vivette D D'Agati; Jonathan A Winston; Mary E Klotman; Paul E Klotman Journal: J Am Soc Nephrol Date: 2000-11 Impact factor: 10.121
Authors: Lynda Anne Szczech; Samir K Gupta; Ramez Habash; Antonio Guasch; Robert Kalayjian; Richard Appel; Timothy A Fields; Laura P Svetkey; Katherine H Flanagan; Paul E Klotman; Jonathan A Winston Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Christina M Wyatt; Susan Morgello; Rebecca Katz-Malamed; Catherine Wei; Mary E Klotman; Paul E Klotman; Vivette D D'Agati Journal: Kidney Int Date: 2008-12-03 Impact factor: 10.612
Authors: Christina M Wyatt; Jonathan A Winston; Carlos D Malvestutto; Dawn A Fishbein; Irina Barash; Alan J Cohen; Mary E Klotman; Paul E Klotman Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: Chirag R Parikh; Alkesh Jani; Vyacheslav Y Melnikov; Sarah Faubel; Charles L Edelstein Journal: Am J Kidney Dis Date: 2004-03 Impact factor: 8.860
Authors: Vasantha Jotwani; Michael G Shlipak; Rebecca Scherzer; Rulan S Parekh; W H Linda Kao; Michael Bennett; Mardge H Cohen; Marek Nowicki; Anjali Sharma; Mary Young; Phyllis C Tien; Chirag R Parikh; Michelle M Estrella Journal: Am J Kidney Dis Date: 2015-04-24 Impact factor: 8.860
Authors: Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Michael G Shlipak; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael R Bennett; Chirag R Parikh; Joachim H Ix; Vasantha Jotwani Journal: Am J Nephrol Date: 2019-09-25 Impact factor: 3.754
Authors: Simon B Ascher; Rebecca Scherzer; Arvind Nishtala; Vasantha Jotwani; Carl Grunfeld; Chirag R Parikh; Derek Ng; Ruibin Wang; Frank J Palella; Michael G Shlipak; Michelle M Estrella Journal: J Acquir Immune Defic Syndr Date: 2019-10-01 Impact factor: 3.731
Authors: Yisel M Cantres-Rosario; Valerie Wojna; Rafael Ruiz; Bexaida Diaz; Miriam Matos; Rosa J Rodriguez-Benitez; Elaine Rodriguez; Richard L Skolasky; Yamil Gerena Journal: Front Neurol Date: 2022-06-02 Impact factor: 4.086
Authors: Anthony N Muiru; Rebecca Scherzer; Simon B Ascher; Vasantha Jotwani; Carl Grunfeld; Judy Shigenaga; Kimberly A Spaulding; Derek K Ng; Deborah Gustafson; Amanda B Spence; Anjali Sharma; Mardge H Cohen; Chirag R Parikh; Joachim H Ix; Michelle M Estrella; Michael G Shlipak Journal: BMC Nephrol Date: 2021-08-30 Impact factor: 2.585
Authors: S B Ascher; R Scherzer; M M Estrella; A N Muiru; V K Jotwani; C Grunfeld; J Shigenaga; K A Spaulding; D K Ng; D Gustafson; A B Spence; A Sharma; M H Cohen; C R Parikh; J H Ix; M G Shlipak Journal: HIV Med Date: 2021-03-09 Impact factor: 3.094
Authors: Mohammed I Danjuma; Shaikha Al Shokri; Nadia Bakhsh; Mohammed A Alamin; Mohamed Gh Mohamedali; Igbiks Tamuno Journal: Int J STD AIDS Date: 2020-09-21 Impact factor: 1.359
Authors: Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Vasantha K Jotwani; Judy Shigenaga; Kimberly A Spaulding; Derek K Ng; Deborah Gustafson; Amanda B Spence; Anjali Sharma; Mardge H Cohen; Chirag R Parikh; Joachim H Ix; Michael G Shlipak Journal: Kidney Med Date: 2021-04-17
Authors: X Q Le; D P Liu; J Chen; Z Y Gong; J N Xun; J R Wang; J J Sun; C Steinhart; L Liu; Y Z Shen; T K Qi; Z Y Wang; X Zhang; Y Tang; W Song; H Z Lu; R F Zhang Journal: HIV Med Date: 2021-06-10 Impact factor: 3.180